<!doctype html>
<html lang="en-us" >
<head>
    <meta charset="utf-8">
    <title>Genentech: Press Releases | Friday, Jun 20, 2025</title>
    <meta name="description" content="Discover the latest news about our company, our products, our policies, and our people.">
    <link href="https://feeds.feedburner.com/Genentech-Stories" rel="alternate" type="application/rss+xml" title="Genentech - Read about breakthrough science, the everyday people who make it happen, and the patients we serve." />
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta property="og:title" content="Genentech: Press Releases | Friday, Jun 20, 2025" />
    <meta property="og:description" content="Discover the latest news about our company, our products, our policies, and our people." />
    <meta property="og:image" content="https://www.gene.com/assets/frontend/img/social.png" />
    
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:site" content="@genentech">
    <meta name="twitter:title" content="Genentech: Press Releases | Friday, Jun 20, 2025">
    <meta name="twitter:description" content="Discover the latest news about our company, our products, our policies, and our people.">
    <meta name="twitter:creator" content="@genentech">
    <meta name="twitter:image:src" content="https://www.gene.com/assets/frontend/img/social.png">
    <meta name="csrf-token" content="">

    <script data-icons="/assets/frontend/svg/icons.svg"></script>
    <link rel="preload" as="style" href="https://www.gene.com/build/assets/v3-main-site-BRPulBvN.css" /><link rel="stylesheet" href="https://www.gene.com/build/assets/v3-main-site-BRPulBvN.css" />
    
    <link rel="icon" href="/assets/frontend/img/favicon.ico">
    <link rel="apple-touch-icon-precomposed" href="/assets/frontend/img/apple-icon-touch.png">
    <link rel="sitemap" type="application/xml" title="Sitemap" href="/sitemap" />
    <link rel="stylesheet" href="https://www.gene.com/assets/frontend/css/custom/galaxySearch.css" />

            <link rel="canonical" href="https://www.gene.com/media/press-releases/15069/2025-06-20/genentechs-lunsumio-and-polivy-combinati">
    
  <style>
  .fit-vids-style {
    display: none;
  }
  </style>

    <script>
    var jQ = {
        queue: [],
        ready: function (f) {
            if (typeof f=='function') jQ.queue.push(f);
            return jQ;
            },
        unq: function () {
            for (var i = 0; i < jQ.queue.length; i++) jQ.queue[i]();
            jQ.queue = null;
        }
    };
    if (typeof window.jQuery == 'undefined') { window.jQuery = window.$ = jQ.ready; }
    var Gene = { universal: {}, configs: {}, main: {}, features: {}, custom: {}, analytics: {} };
    Gene.configs.paths = {
        prepend : '/'
    }
  </script>

  <!-- OneTrust Cookies Consent Notice start for www.gene.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="0fd064ad-a247-479a-9e43-5ca8b40bcb43" ></script>
<script type="text/javascript">
function OptanonWrapper() { }
</script>
<!-- OneTrust Cookies Consent Notice end for www.gene.com -->

  <script>
    var isReturningUser = false;

    if (window.localStorage) {
       isReturningUser = localStorage.getItem('RETURNING_USER') != null;
       localStorage.setItem('RETURNING_USER', true);
    }

    var referrer = 'direct';
    if (document.referrer && document.referrer != "") {
      referrer = document.referrer;
    }

    var dataLayer = [{
      'userType': isReturningUser ? 'returning' : 'new',
      'referrer': referrer,
            'contentID': 'node-dc4c68e2-39e0-43f8-951d-9699f32fc71e',
                        'contentID': 'node-dc4c68e2-39e0-43f8-951d-9699f32fc71e',
          }];
      </script>

<link rel="modulepreload" href="https://www.gene.com/build/assets/analytics-standalone-BYsXlnmL.js" /><script  src="https://www.gene.com/build/assets/analytics-standalone-BYsXlnmL.js"></script>

<script type="text/javascript">

    function getQueryParam(str) {
       var v = window.location.search.match(new RegExp('(?:[\?\&]'+str+'=)([^&]+)'));
       return v ? v[1] : null;
    }
    var src = getQueryParam('src');

    if (src) {
        Gene.analytics.setSource('Source', src);
    }

    
</script>
  <script src="https://cdn.jsdelivr.net/gh/alpinejs/alpine@v2.x.x/dist/alpine.min.js" defer></script>
</head>

<body class=" ">
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-PPKDWPC');</script>
<!-- End Google Tag Manager -->
<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PPKDWPC"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->

<header id='gene-header' class='header'></header>
<div class="l-page-overlay"></div>

<script>
    // @todo: This is temporary code - to be moved to separate file (both css & js).
    var relatedTranslations = [];
    var currentLangId = 'en';
    var langSwitchLabels = {};;

    $(document).ready(function () {
        if (relatedTranslations.length > 0) {
            var selector = $('<select data-minimum-results-for-search="50" data-width="resolve" style="margin-top: -15px; width: 160px;"></select>');

            selector.append($('<option>' + (langSwitchLabels[currentLangId] ?? currentLangId) + '</option>'));

            relatedTranslations.forEach(function (translation) {
                selector.append($('<option value="' + translation.calculated_path + '">' + (langSwitchLabels[translation.lang_id] ?? translation.lang_id) + '</option>'));
            });

            selector.on('change', function () {
                if ($(this).val().length > 0) {
                    window.location = '/switch?request_path=' + $(this).val();
                }
            });

            var breadcrumbs = $('.js-nav-container .breadcrumbs').first();

            if (breadcrumbs) {
                var container = $('<div class="lang-switch-container" style="display: flex; flex-direction: row; justify-content: space-between; align-content: flex-start;"></div>');
                container.append(breadcrumbs.clone());
                container.append(selector);

                breadcrumbs.hide();
                breadcrumbs.after(container);
            }
        }
    });
</script>
<style>
    .lang-switch-container {
        margin-bottom: 10px;
    }
    .lang-switch-container .select2-container {
        position: relative;
        top: -13px;
    }
    .lang-switch-container .select2-container .select2-selection--single {
        margin-top: 0px;
    }
    .lang-switch-container .select2-container--default .select2-selection--single .select2-selection__arrow {
        top: -10px;
    }
</style>
<div class="ie-warning" style="display:none;">
    <div class="ie-warning__container constrained">
        <h2 class="ie-warning__text">Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.</h2>
    </div>
</div>

<!--Commented out til next closure
-->


<div class="header__spacer "></div>

<div class="js-nav-container ">
    <script type="text/javascript">
    Gene.analytics.setAudience('media');
</script>

<div class="constrained">
        <div style="position: absolute; width: 260px; height: 100%;">
            <div class="l-rail-left">
                
                <div class="nav-secondary-container">
                                            <nav class="nav-secondary js-nav-secondary">
                    <div class="nav-secondary__header ">
                <a class="nav-secondary__link" href="/media">Media</a>
            </div>
                
                    
            <ul class="nav-secondary__children">
                                                                                        
                            <li class="nav-secondary__child ">
                                <a class="nav-secondary__link" href="/media/news-features">News Features</a>
                            </li>
                                                                                                                                    
                            <li class="nav-secondary__child current">
                                <a class="nav-secondary__link" href="/media/press-releases">Press Releases</a>
                            </li>
                                                                                                                                    
                            <li class="nav-secondary__child ">
                                <a class="nav-secondary__link" href="/media/statements">Statements</a>
                            </li>
                                                                                                                                    
                            <li class="nav-secondary__child ">
                                <a class="nav-secondary__link" href="/media/company-information">Company Information</a>
                            </li>
                                                                                                                                    
                            <li class="nav-secondary__child ">
                                <a class="nav-secondary__link" href="/media/news-alerts">Sign Up For News Alerts</a>
                            </li>
                                                                        </ul>
            </nav>
                    
                                        <aside class="nav-secondary__media-inquiries">
                        <div class="nav-secondary__media-inquiries-header">Media Inquiries</div>
                        <a id="start-new-submission" class="button" href="/contact-us/submit-media-inquiry">
                            Email Us <svg class="icon nav-secondary__button-icon"><use xlink:href="#icon-share-email"></use></svg>
                        </a>
                    </aside>
                                    </div>
            </div>
        </div>
    </div>

<div class="constrained press-release">
    <div class="l-grid">

        <div class="l-content-container">
            <div class="l-content">
                <div class="breadcrumbs">
                        <a href="/media">Media</a> /
                <a href="/media/press-releases">Press Releases</a>
</div>

                <div class="block-basic">
                    <p>Friday, Jun 20, 2025</p>

                    <h2>Genentechâ€™s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-Cell Lymphoma</h2>                    <h3><p>&nbsp;Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival&nbsp;&ndash;&nbsp;three times longer than R-GemOx</p><p>&nbsp;</p><p>This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care</p><p>&nbsp;</p><p>Results will be submitted to global health authorities including the U.S. Food and Drug Administration</p></h3>                                        
                    <p><b> South San Francisco, CA -- June 20, 2025 -- </b></p>                    <p>Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [<a href="https://clinicaltrials.gov/study/NCT05171647">NCT05171647</a>] study showing Lunsumio<sup>&reg;</sup> (mosunetuzumab-axgb) administered subcutaneously in combination with Polivy<sup>&reg;</sup> (polatuzumab vedotin-piiq) demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR) compared to Rituxan<sup>&reg;</sup> (rituximab), gemcitabine and oxaliplatin (R-GemOx), in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who are not eligible for transplant. Primary analysis data were featured at the 18<sup>th</sup> International Conference on Malignant Lymphoma as a late-breaking oral presentation.</p><p>&nbsp;</p><p>Results from the SUNMO study will be submitted to global health authorities, including the U.S. Food and Drug Administration (FDA). The National Comprehensive Cancer Network<sup>&reg;</sup> (NCCN<sup>&reg;</sup>) has recently added Lunsumio and Polivy to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&reg;</sup>) as a category 2A recommendation for the treatment of people with second-line (2L) diffuse large B-cell lymphoma (DLBCL) who are not intended to proceed to transplant.<sup>&dagger;</sup></p><p>&nbsp;</p><p>&ldquo;Lunsumio and Polivy represent the first combination of a bispecific antibody and antibody-drug conjugate, which could avoid chemotherapy and potentially provide an alternative option for some patients with relapsed or refractory LBCL,&rdquo; said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. &ldquo;We are also encouraged by the favorable safety profile and potential for outpatient use of this regimen, which may suit diverse patient and healthcare system needs.&rdquo;</p><p>&nbsp;</p><p>At a median follow-up of 23.2 months, the Lunsumio and Polivy combination demonstrated a 59% reduction in risk of disease progression or death compared to R-GemOx (hazard ratio [HR] 0.41, 95% confidence interval [CI]: 0.28&ndash;0.61; p&lt;0.0001).<sup>&nbsp;</sup>Median PFS was three times longer with Lunsumio and Polivy at 11.5 months (95% CI: 5.6-17.6), compared to 3.8 months for R-GemOx (95% CI: 2.9-4.1) and 12-month PFS was more than doubled at 48.5% (95% CI: 39.6-57.4) vs.17.8% (95% CI: 5.4-30.3), respectively. This PFS benefit was consistent across subgroups, including in high-risk patients with primary refractory disease (HR 0.46, 95% CI: 0.29&ndash;0.72).<sup>&nbsp;</sup> At the interim analysis, overall survival (OS) data were not yet mature. OS numerically favored the Lunsumio and Polivy combination with a median of 18.7 months (95% CI: 14.1&ndash;not evaluable [NE]) compared to 13.6 months for R-GemOx (95% CI: 9.9&ndash;NE; HR 0.80; 95% CI: 0.54 - 1.20).<sup>&nbsp;</sup></p><p>&nbsp;</p><p>&ldquo;There remains a clear need for effective and well-tolerated treatments for people with this difficult-to-treat disease,&rdquo; said Jason Westin, professor of lymphoma and director of lymphoma clinical research, The University of Texas, MD Anderson Cancer Center. &ldquo;If approved, this off-the-shelf treatment combination of mosunetuzumab-axgb and polatuzumab vedotin-piiq could be administered over a fixed period of time, without mandatory hospitalization or traditional chemotherapy, which could provide a meaningful option for patients with relapsed or refractory LBCL.&rdquo;</p><p>&nbsp;</p><p>In the Lunsumio and Polivy arm, 30% more patients achieved an objective response (70.3%, 95% CI: 61.9-77.8) compared to R-GemOx (40.0%; 95% CI: 28.5-52.4), and the complete response rate was doubled at 51.4% (95% CI: 42.8-60.0) versus 24.3% (95% CI: 14.8-36.0).<sup>&nbsp;</sup>Nearly 75% of patients with a complete response were still in remission after one year (72.6%; 95% CI: 61.4-83.8) compared to 44.1% for R-GemOx (95% CI: 13.2-74.9).</p><p>&nbsp;</p><p>The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines, potentially allowing use across outpatient and community settings. The incidence of cytokine release syndrome (CRS) events in the Lunsumio plus Polivy arm was low, occurring in one in four patients, with less than 5% of patients experiencing Grade 2 or 3 CRS events. No immune effector cell-associated neurotoxicity syndrome events were reported. Rates of Grade 3&ndash;4 (58.5% vs. 57.8%) and Grade 5 (5.2% vs. 6.3%) adverse events (AEs) were similar between the combination and R-GemOx, with fewer AEs leading to treatment discontinuation in the Lunsumio and Polivy arm (2.2% vs. 4.7%).</p><p>&nbsp;</p><p>High-dose chemotherapy followed by stem-cell transplant has traditionally been the standard 2L treatment for people with R/R LBCL. While 2L therapies have advanced, DLBCL can progress rapidly and many people are not candidates for, cannot tolerate, or do not have access to latest therapies. There is an urgent need for treatments that are rapidly available upon a diagnosis of relapse, that can manage the disease and improve long-term outcomes.</p><p>&nbsp;</p><p>Genentech&rsquo;s lymphoma portfolio is one of the broadest in the industry, providing a unique and much-needed opportunity to combine regimens with different and complementary mechanisms of action. We are exploring our CD20xCD3 bispecifics, Lunsumio and Columvi<sup>&reg;</sup> (glofitamab-gxbm), alongside Polivy to move one step closer towards our goal of improving the lives of as many patients with lymphomas as possible. This includes the Phase III STARGLO study [<a href="https://www.clinicaltrials.gov/ct2/show/NCT04408638">NCT04408638</a>] evaluating the efficacy and safety of Columvi<sup>&nbsp;</sup>in combination with GemOx versus R-GemOx alone in patients with R/R DLBCL who have received at least one prior line of therapy and who are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.</p><p>&nbsp;</p><p>Lunsumio is already approved for people with R/R follicular lymphoma after two or more lines of therapy in more than 60 countries worldwide. Polivy in combination with R-CHP is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL) in more than 100 countries worldwide and in combination with bendamustine and Rituxan for R/R DLBCL in more than 90 countries worldwide.</p><p>&nbsp;</p><p><em>&dagger;NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way</em></p><p><strong>&nbsp;</strong></p><p><strong>About the SUNMO study<br></strong>The SUNMO [<a href="https://clinicaltrials.gov/study/NCT05171647">NCT05171647</a>] study is an international, multi-center, randomized Phase III trial evaluating the efficacy and safety of subcutaneously administered Lunsmio<sup>&reg;</sup> (mosunetuzumab-axgb) in combination with intravenous Polivy<sup>&reg;</sup> (polatuzumab vedotin-piiq) compared to Rituxan<sup>&reg;</sup> (rituximab), gemcitabine and oxaliplatin (R-GemOx), in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who are not eligible for autologous stem cell transplant. Outcome measures include progression-free survival and objective response rate (dual primary endpoints), overall survival, duration of objective response, complete response rate, duration of complete response, safety and tolerability, and patient-reported outcomes.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>About&nbsp;Lunsumio<sup>&reg;</sup> (mosunetuzumab-axgb)&nbsp;</strong><br>Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual-targeting activates and redirects a patient&rsquo;s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, and other indications.</p><p>&nbsp;</p><p><strong>About&nbsp;Polivy<sup>&reg;</sup> (polatuzumab vedotin-piiq)</strong><br>Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed in the majority of B cells, an immune cell impacted in some types of non-Hodgkin lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as those expressing CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL.</p><p>&nbsp;</p><p><strong>About large B-cell lymphoma (LBCL)</strong></p><p>Large B-cell lymphomas (LBCL), composed predominantly of diffuse large B-cell lymphoma (DLBCL), are the most common type of non-Hodgkin lymphoma (NHL) that affect B-cell lymphocytes, a type of white blood cells. DLBCL is the most common form of aggressive NHL and makes up about 80% of LBCLs. While it can arise in lymph nodes, it can also occur in organs outside of the lymphatic system. Approximately 160,000 people worldwide are diagnosed with DLBCL each year, with comparable incidence rates across regions. Medical practices, including pathological classification, diagnosis, staging, initial treatment and relapse management, are similarly approached worldwide. <sup>&nbsp;</sup>While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. Improving treatments earlier in the course of the disease and providing much needed alternative options could help to improve long-term outcomes.</p><p>&nbsp;</p><p>Lunsumio U.S. Indication</p><p>Lunsumio (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer.</p><p>&nbsp;</p><p>It is not known if Lunsumio is safe and effective in children.&nbsp;</p><p>&nbsp;</p><p>The conditional approval of Lunsumio is based on response rate. There are ongoing studies to establish how well the drug works.</p><p>&nbsp;</p><p><strong>What is the most important information I should know about Lunsumio?</strong></p><p><strong>&nbsp;</strong></p><p><strong>Lunsumio may cause Cytokine Release Syndrome (CRS),&nbsp;</strong>a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening.</p><p>&nbsp;</p><p><strong>Get medical help right away if you develop any signs or symptoms of CRS at any time, including:&nbsp;</strong></p><ul><li>fever of 100.4&deg;F (38&deg;C) or higher</li><li>chills</li><li>low blood pressure</li><li>fast or irregular heartbeat</li><li>tiredness or weakness</li><li>difficulty breathing</li><li>headache</li><li>confusion</li><li>feeling anxious</li><li>dizziness or light-headedness</li><li>nausea</li><li>vomiting</li></ul><p>&nbsp;</p><p><strong>Due to the risk of CRS, you will receive Lunsumio on a &ldquo;step-up dosing schedule.&rdquo;</strong></p><ul><li>The step-up dosing schedule is when you receive smaller &ldquo;step-up&rdquo; doses of Lunsumio on Day 1 and Day 8 of your first cycle of treatment</li><li>You will receive a higher dose of Lunsumio on Day 15 of your first cycle of treatment</li><li>If your dose of Lunsumio is delayed for any reason, you may need to repeat the step-up dosing schedule</li><li>Before each dose in Cycle 1 and Cycle 2, you will receive medicines to help reduce your risk of CRS</li></ul><p>&nbsp;</p><p>Your healthcare provider will check you for CRS during treatment with Lunsumio and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio, if you have severe side effects.</p><p>&nbsp;</p><p><strong>What are the possible side effects of Lunsumio?</strong></p><p><strong>&nbsp;</strong></p><p><strong>Lunsumio may cause serious side effects, including:</strong></p><ul><li><strong>neurologic problems. Lunsumio can cause serious and life-threatening neurological problems.&nbsp;</strong>Your healthcare provider will check you for neurologic problems during treatment with Lunsumio. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems during or after treatment with Lunsumio, including:<ul style="list-style-type: circle;"><li>headache</li><li>numbness and tingling of the arms, legs, hands, or feet</li><li>dizziness</li><li>confusion and disorientation</li><li>difficulty paying attention or understanding things</li><li>forgetting things or forgetting who or where you are</li><li>trouble speaking, reading, or writing</li><li>sleepiness or trouble sleeping</li><li>tremors</li><li>loss of consciousness</li><li>seizures</li><li>muscle problems or muscle weakness</li><li>loss of balance or trouble walking</li><li>tiredness</li></ul></li><li><strong>serious infections.</strong>&nbsp;Lunsumio can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with Lunsumio, including:<ul style="list-style-type: circle;"><li>fever of 100.4&deg; F (38&deg; C) or higher</li><li>cough</li><li>chest pain</li><li>tiredness</li><li>shortness of breath</li><li>painful rash</li><li>sore throat</li><li>pain during urination</li><li>feeling weak or generally unwell</li></ul></li><li><strong>hemophagocytic lymphohistiocytosis (HLH)</strong>. Lunsumio can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with Lunsumio. Your health care provider will check you for HLH especially if your CRS lasts longer than expected. Signs and symptoms of HLH include:<ul style="list-style-type: circle;"><li>fever</li><li>enlarged spleen</li><li>easy bruising</li><li>low blood cell counts</li><li>liver problems</li></ul></li><li><strong>low blood cell counts.</strong>&nbsp;Low blood cell counts are common during treatment with Lunsumio and can also be serious or severe. Your healthcare provider will check your blood cell counts during treatment with Lunsumio. Lunsumio can cause the following low blood cell counts:<ul style="list-style-type: circle;"><li><strong>low white blood cell counts (neutropenia).&nbsp;</strong>Low white blood cells can increase your risk for infection</li><li><strong>low red blood cell counts (anemia).</strong>&nbsp;Low red blood cells can cause tiredness and shortness of breath</li><li><strong>low platelet counts (thrombocytopenia).</strong>&nbsp;Low platelet counts can cause bruising or bleeding problems</li></ul></li><li><strong>growth in your tumor or worsening of tumor related problems (tumor flare).</strong>&nbsp;Lunsumio can cause serious or severe worsening of your tumor. Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment with Lunsumio:<ul style="list-style-type: circle;"><li>chest pain</li><li>cough</li><li>trouble breathing</li><li>tender or swollen lymph nodes</li><li>pain or swelling at the site of the tumor</li></ul></li></ul><p><strong>&nbsp;</strong></p><p><strong>Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio if you develop severe side effects.</strong></p><p>&nbsp;</p><p><strong>The most common side effects of Lunsumio include:</strong>&nbsp;tiredness, rash, fever, and headache.</p><p>&nbsp;</p><p><strong>The most common severe abnormal blood test results with Lunsumio include:</strong>&nbsp;decreased phosphate, increased glucose, and increased uric acid levels.</p><p>&nbsp;</p><p><strong>Before receiving Lunsumio, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><ul><li>have ever had an infusion reaction after receiving Lunsumio</li><li>have an infection, or have had an infection in the past which lasted a long time or keeps coming back</li><li>have or have had Epstein-Barr Virus</li><li>are pregnant or plan to become pregnant. Lunsumio may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lunsumio</li></ul><p style="margin-left: 40px;"><strong>Females who are able to become pregnant:</strong></p><ul style="list-style-type: circle;"><li style="margin-left: 20px;">your healthcare provider should do a pregnancy test before you start treatment with Lunsumio</li><li style="margin-left: 20px;">you should use an effective method of birth control (contraception) during your treatment and for 3 months after the last dose of Lunsumio</li></ul><ul><li>are breastfeeding or plan to breastfeed. It is not known if Lunsumio passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of Lunsumio</li></ul><p>&nbsp;</p><p><strong>Tell your healthcare provider about all the medicines you take,&nbsp;</strong>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>What should I avoid while receiving Lunsumio?</strong></p><p><strong>Do not</strong>&nbsp;drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.</p><p>&nbsp;</p><p>These are not all the possible side effects of Lunsumio. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio.</p><p>&nbsp;</p><p><strong>You may report side effects to the FDA at (800) FDA-1088 or&nbsp;</strong><a href="http://www.fda.gov/medwatch"><strong>http://www.fda.gov/medwatch</strong></a><strong>. You may also report side effects to Genentech at (888) 835-2555.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full&nbsp;</strong><a href="https://www.gene.com/download/pdf/lunsumio_prescribing.pdf"><strong>Prescribing Information</strong></a><strong>&nbsp;and&nbsp;</strong><a href="https://www.gene.com/download/pdf/lunsumio_medguide.pdf"><strong>Medication Guide</strong></a><strong>&nbsp;or visit&nbsp;</strong><a href="https://www.lunsumio.com/"><strong>https://www.Lunsumio.com</strong></a><strong>.</strong></p><p>&nbsp;</p><p>Polivy U.S. Indication</p><p>Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL).</p><p>&nbsp;</p><p>Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies.</p><p><strong>&nbsp;</strong></p><p><strong>Important Safety Information</strong></p><p><strong>Possible serious side effects</strong></p><p>Everyone reacts differently to Polivy therapy, so it&rsquo;s important to know what the side effects are.<strong>&nbsp;Some people who have been treated with Polivy have experienced serious to fatal side effects.&nbsp;</strong>Your doctor may stop or adjust your treatment if any serious side effects occur.<strong>&nbsp;Be sure to contact your healthcare team if there are any signs of these side effects.</strong></p><ul><li><strong>Nerve problems in your arms and legs:&nbsp;</strong>This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern</li><li><strong>Infusion-related reactions:&nbsp;</strong>You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion</li><li><strong>Low blood cell counts:&nbsp;</strong>Treatment with Polivy can cause severe low blood cell counts. Your doctor will monitor your blood counts throughout treatment with Polivy</li><li><strong>Infections:&nbsp;</strong>If you have a fever of 100.4&deg;F (38&deg;C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you Polivy, which may prevent some infections&nbsp;</li><li><strong>Rare and serious brain infections:&nbsp;</strong>Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes</li><li><strong>Tumor lysis syndrome:&nbsp;</strong>Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy</li><li><strong>Potential harm to liver:&nbsp;</strong>Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication</li></ul><p><strong>&nbsp;</strong></p><p><strong>Side effects seen most often</strong></p><p>The most common side effects during treatment were</p><ul><li>Nerve problems in arms and legs</li><li>Nausea</li><li>Tiredness or lack of energy</li><li>Diarrhea</li><li>Constipation</li><li>Hair loss</li><li>Redness and sores of the lining of the mouth, lips, throat, and digestive tract</li></ul><p><strong>&nbsp;</strong></p><p>Polivy may lower your red or white blood cell counts and increase uric acid levels.</p><p><strong>&nbsp;</strong></p><p><strong>Polivy may not be for everyone. Talk to your doctor if you are</strong></p><ul><li><strong>Pregnant or think you are pregnant:&nbsp;</strong>Data have shown that Polivy may harm your unborn baby</li><li><strong>Planning to become pregnant:&nbsp;</strong>Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for 5 months after their last Polivy treatment</li><li><strong>Breastfeeding:&nbsp;</strong>Women should not breastfeed while taking Polivy and for 2 months after the last dose</li></ul><p><strong>&nbsp;</strong></p><p>These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>You may report side effects to the FDA at (800) FDA-1088 or&nbsp;</strong><a href="http://www.fda.gov/medwatch"><strong>http://www.fda.gov/medwatch</strong></a><strong>. You may also report side effects to Genentech at (888) 835-2555.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Please see the&nbsp;</strong><a href="https://www.gene.com/download/pdf/polivy_prescribing.pdf"><strong>full Prescribing Information</strong></a><strong>&nbsp;and visit&nbsp;</strong><a href="https://www.polivy.com/"><strong>https://www.Polivy.com</strong></a><strong>&nbsp;for additional Important Safety Information.</strong></p><p><strong>&nbsp;</strong></p><p><strong>About Columvi&reg; (glofitamab-gxbm)<br>Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech&rsquo;s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program that also includes Lunsumio&reg; (mosunetuzumab-axgb), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Columvi U.S. Indication</strong></p><p>Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer.</p><p>&nbsp;</p><p>It is not known if Columvi is safe and effective in children.</p><p>&nbsp;</p><p>The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works.</p><p>&nbsp;</p><p><strong>What is the most important information I should know about Columvi?</strong></p><p>&nbsp;</p><p><strong>Columvi can cause Cytokine Release Syndrome (CRS),</strong>&nbsp;a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including:</strong></p><ul><li>fever of 100.4&deg;F (38&deg;C) or higher</li><li>chills or shaking</li><li>fast or irregular heartbeat</li><li>dizziness or light-headedness&nbsp;</li><li>trouble breathing</li><li>shortness of breath</li></ul><p>&nbsp;</p><p><strong>Due to the risk of CRS, you will receive Columvi on a &ldquo;step-up dosing schedule&rdquo;.</strong></p><ul><li>A single dose of a medicine called obinutuzumab will be given to you on the first day of your first treatment cycle (Day 1 of Cycle 1).&nbsp;</li><li>You will start the Columvi step-up dosing schedule a week after the obinutuzumab dose. The step-up dosing schedule is when you receive smaller &ldquo;step-up&rdquo; doses of Columvi on Day 8 and Day 15 of Cycle 1. This is to help reduce your risk of CRS. You should be hospitalized during your infusion and for 24 hours after receiving the first step-up dose on Day 8. You should be hospitalized during your infusion and for 24 hours after receiving the second step-up dose on Day 15 if you experienced CRS during the first step-up dose.</li><li>You will receive your first full dose of Columvi a week after the second step-up dose (this will be Day 1 of Cycle 2).</li><li>If your dose of Columvi is delayed for any reason, you may need to repeat the &ldquo;step-up dosing schedule&rdquo;.&nbsp;</li><li>If you had more than mild CRS with your previous dose of Columvi, you should be hospitalized during and for 24 hours after receiving your next dose of Columvi.</li><li>Before each dose of Columvi, you will receive medicines to help reduce your risk of CRS and infusion-related reactions.</li></ul><p>Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects.</p><p>&nbsp;</p><p><strong>Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers.</strong>&nbsp;The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away.&nbsp;</p><p>&nbsp;</p><p><strong>What are the possible side effects of Columvi?</strong></p><p><strong>&nbsp;</strong></p><p><strong>Columvi may cause serious side effects, including:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong></p><ul><li><strong>Cytokine Release Syndrome.&nbsp;</strong></li><li><strong>Neurologic problems.</strong>&nbsp;Columvi can cause serious neurologic problems that may lead to death. Your healthcare provider will monitor you for neurologic problems during treatment with Columvi. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:</li></ul><ul style="list-style-type: circle;"><li style="margin-left: 40px;">headache</li><li style="margin-left: 40px;">confusion and disorientation&nbsp;</li><li style="margin-left: 40px;">difficulty paying attention or understanding things</li><li style="margin-left: 40px;">trouble speaking&nbsp;</li><li style="margin-left: 40px;">sleepiness</li><li style="margin-left: 40px;">memory problems</li><li style="margin-left: 40px;">numbness, tingling, or weakness of the hands or feet</li><li style="margin-left: 40px;">dizziness</li><li style="margin-left: 40px;">shaking (tremors)</li></ul><ul><li><strong>Serious Infections.</strong>&nbsp;Columvi can cause serious infections that may lead to death. Your healthcare provider will monitor you for signs and symptoms of infection and treat you as needed. Tell your healthcare provider right away if you develop any signs of an infection, including: fever, chills, weakness, cough, shortness of breath, or sore throat.</li><li><strong>Growth in your tumor or worsening of tumor related problems (tumor flare).</strong>&nbsp;Tell your healthcare provider if you get any of these signs or symptoms of tumor flare:&nbsp;<ul><li>tender or swollen lymph nodes</li><li>pain or swelling at the site of the tumor</li><li>chest pain</li><li>cough</li><li>trouble breathing</li></ul></li></ul><p>&nbsp;</p><p>&nbsp;<strong>The most common side effects of Columvi include:&nbsp;</strong>CRS, muscle and bone pain, rash, and tiredness.</p><p><strong>The most common severe abnormal lab test results with Columvi include:</strong>&nbsp;decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting).&nbsp;</p><p>&nbsp;</p><p>Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects.&nbsp;</p><p>&nbsp;</p><p><strong>Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><ul><li>have an infection</li><li>have kidney problems</li><li>are pregnant or plan to become pregnant. Columvi may harm your unborn baby</li><li><strong>Females who are able to become pregnant:</strong><ul><li>Your healthcare provider should do a pregnancy test before you start treatment with Columvi.&nbsp;</li><li>You should use effective birth control (contraception) during treatment and for 1 month after your last dose of Columvi. Talk to your healthcare provider about what birth control method is right for you during this time.</li><li>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Columvi.</li></ul></li><li>are breastfeeding or plan to breastfeed. Columvi may pass into your breast milk. Do not breastfeed during treatment and for 1 month after your last dose of Columvi.</li></ul><p>&nbsp;</p><p><strong>Tell your healthcare provider about all the medicines you take,&nbsp;</strong>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>What should I avoid while receiving Columvi?</strong></p><p><strong>Do not</strong>&nbsp;drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems.</p><p>&nbsp;</p><p>These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi.&nbsp;</p><p>&nbsp;</p><p><strong>You may report side effects to the FDA at (800) FDA-1088 or&nbsp;</strong><a href="http://www.fda.gov/medwatch"><strong>http://www.fda.gov/medwatch</strong></a><strong>. You may also report side effects to Genentech at (888) 835-2555.</strong></p><p><strong>&nbsp;</strong></p><p>Please see Important Safety Information, including <strong>Serious Side Effects</strong>, as well as the Columvi full&nbsp;<a href="https://www.gene.com/download/pdf/columvi_prescribing.pdf">Prescribing Information</a>&nbsp;and&nbsp;<a href="https://www.gene.com/download/pdf/columvi_medguide.pdf">Medication Guide</a>&nbsp;or visit&nbsp;<a href="https://www.columvi.com">https://www.Columvi.com</a>.</p><p><strong><br>&nbsp;</strong></p><p><strong>About Genentech in hematology</strong></p><p>For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we&rsquo;re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit&nbsp;<a href="https://www.gene.com/hematology">http://www.gene.com/hematology</a>.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>About Genentech</strong></p><p>Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Genentech Group, has headquarters in South San Francisco, California. For additional information about the company, please visit&nbsp;<a href="https://www.gene.com/">http://www.gene.com</a>.</p><p>&nbsp;</p><p style="text-align: center;">###</p>
                </div>
            </div>

            <div class="l-rail-right">
                                    <div class="">
        <div class="tile-grid">

                        <div class="tile-grid__tile">
                <a class="v3-tile v3-tile-text content-tile" href="/medical-professionals/pipeline">
    <div class="aspect aspect--3x4@md aspect--3x4@sm aspect--3x4@xs">
        <div class="aspect-inner">
            <div class="content-tile__wrap tile__wrap height-full">
                <h1 class="v3-tile-content__head type--center">Our Pipeline</h1>
                <div class="v3-tile-content__divider"></div>
                <p class="v3-tile-content__body type--center" style="text-align: center;">Our pipeline includes new molecular entities that address serious unmet medical needs.</p>

                                    <div class="v3-tile__corner-icon">
                        
                    </div>
                            </div>
        </div>
    </div>
</a>            
    
    

            </div>
                        <div class="tile-grid__tile">
                <a class="v3-tile v3-tile-text content-tile" href="/media/company-information/approvals-timeline">
    <div class="aspect aspect--3x4@md aspect--3x4@sm aspect--3x4@xs">
        <div class="aspect-inner">
            <div class="content-tile__wrap tile__wrap height-full">
                <h1 class="v3-tile-content__head type--center">Approvals Timeline</h1>
                <div class="v3-tile-content__divider"></div>
                <p class="v3-tile-content__body type--center" style="text-align: center;">A look at our approvals past and present.</p>

                                    <div class="v3-tile__corner-icon">
                        
                    </div>
                            </div>
        </div>
    </div>
</a>            
    
    

            </div>
            
        </div>
    </div>
    
    
                            </div>
        </div>
    </div>
</div>
</div>

<script>window.GeneJs = window.GeneJs || {};GeneJs.currentNode = {"rootNode":{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":46,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.secondaryNavNode = {"title":"Press Releases","requestPath":"media\/press-releases","ancestors":[{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":46,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}],"shouldShow":true};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.geneHeader = {"topNavNodes":{"3":{"id":"033e314b-6cfd-4977-9449-383a7a165faa","parent_id":"0","title":"Patients","node_type":"static","request_path":"patients","lang_id":"en","source_translation_id":"86a3164e-f08c-11ed-9d94-0242ac150003","target_id":null,"target_path":"","meta_description":"Learn more about our medicines, get help with coverage, and find the right resources for you.","url_suffix":"","position":10,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2021-08-25T22:26:19.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"10":{"id":"59bd7ce6-7a93-4a5b-8ce4-2044dbb5ce7e","parent_id":"0","title":"Medical Professionals","node_type":"static","request_path":"medical-professionals","lang_id":"en","source_translation_id":"86c029be-f08c-11ed-82a4-0242ac150003","target_id":null,"target_path":"","meta_description":"Innovative clinical science. Improved patient care.","url_suffix":"","position":30,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":"","include_js":"","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2019-05-23T21:55:15.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"13":{"id":"982193bc-a3aa-11e7-b779-d0431ef1c812","parent_id":"0","title":"Partners","node_type":"blocks","request_path":"partners","lang_id":"en","source_translation_id":"86cf2608-f08c-11ed-a8ab-0242ac150003","target_id":null,"target_path":"","meta_description":null,"url_suffix":"","position":37,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2017-09-28T00:37:55.000000Z","added_by":"admin","updated_date":"2020-02-25T13:02:07.000000Z","header_image":"","body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"14":{"id":"af5bc686-e327-4030-ade9-a30b7cdde115","parent_id":"0","title":"Scientists","node_type":"blocks","request_path":"scientists","lang_id":"en","source_translation_id":"86d36bd2-f08c-11ed-a4c0-0242ac150003","target_id":null,"target_path":"","meta_description":"Every day our scientists do the work, the relentless incremental labor that could lead to world-changing, life-changing advances.","url_suffix":"","position":43,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2021-03-31T23:54:11.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"16":{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":46,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"18":{"id":"c42ede74-e262-422c-aecd-bce16e4a6201","parent_id":"0","title":"Good","node_type":"blocks","request_path":"good","lang_id":"en","source_translation_id":"86d8438c-f08c-11ed-b055-0242ac150003","target_id":null,"target_path":"","meta_description":"Through the everyday, incremental acts of kindness, we can make great things happen for our communities and our patients.","url_suffix":"","position":48,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2020-05-12T02:58:56.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"21":{"id":"e2b7db24-3c44-11e8-b243-d0431ef1c812","parent_id":"0","title":"Hiring","node_type":"blocks","request_path":"careers","lang_id":"en","source_translation_id":"86dffcc6-f08c-11ed-bb3a-0242ac150003","target_id":null,"target_path":"","meta_description":null,"url_suffix":"","position":59,"prefix":"Now","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2018-04-10T05:25:19.000000Z","added_by":"admin","updated_date":"2020-07-23T22:52:27.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0}}};</script><div class="primary-footer js-nav-footer clearfix">
    <div class="constrained">
        <div class="footer-logo-narrow" data-set="footer-logo">
            <svg aria-label="Genentech - A Member of the Roche Group">
                <use xmlns:xlink="http://www.w3.org/1999/xlink"
                     xlink:href="#icon-genentech-logo"></use>
            </svg>
        </div>
        <nav class="footer-sitemap">
                            <ul>
                    <li class="first-level">
                        <a href="/patients">For Patients</a>
                    </li>
                                                                        <li>
                                <a href="/patients/medicines">Our Medicines</a>
                            </li>
                                                    <li>
                                <a href="/patients/patient-support-services">Patient Support Services</a>
                            </li>
                                                    <li>
                                <a href="/patients/patient-foundation">Genentech Patient Foundation</a>
                            </li>
                                                    <li>
                                <a href="/patients/understanding-insurance">Understanding Insurance and Coverage</a>
                            </li>
                                                    <li>
                                <a href="/patients/clinical-trials">Clinical Trials</a>
                            </li>
                                                    <li>
                                <a href="/patients/medicine-information-support">Medicine Information Support</a>
                            </li>
                                                    <li>
                                <a href="/patients/giving-patients-a-voice">Giving Patients a Voice</a>
                            </li>
                                                    <li>
                                <a href="/patients/disease-education">Disease Education</a>
                            </li>
                                                    <li>
                                <a href="/patients/equitable-care">Equitable Care</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/about-us"> About Us</a>
                    </li>
                                                                        <li>
                                <a href="/about-us/leadership">Leadership</a>
                            </li>
                                                    <li>
                                <a href="/about-us/our-promise">Our Promise</a>
                            </li>
                                                    <li>
                                <a href="/about-us/policy-advocacy">Policy &amp; Advocacy</a>
                            </li>
                                                    <li>
                                <a href="/about-us/oncology">Our Focus on Oncology</a>
                            </li>
                                                    <li>
                                <a href="/about-us/neuroscience">Our Focus on Neuroscience</a>
                            </li>
                                                    <li>
                                <a href="/about-us/ophthalmology">Our Focus on Ophthalmology</a>
                            </li>
                                                    <li>
                                <a href="/about-us/awards-recognition">Awards &amp; Recognition</a>
                            </li>
                                                    <li>
                                <a href="/about-us/investors">Investors</a>
                            </li>
                                                    <li>
                                <a href="/about-us/suppliers">Suppliers</a>
                            </li>
                                                    <li>
                                <a href="/about-us/california-transparency-law">CA Transparency in Supply </a>
                            </li>
                                                    <li>
                                <a href="/about-us/compliance">Compliance Overview</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/contact-us"> Contact Us</a>
                    </li>
                                                                        <li>
                                <a href="/contact-us/call-us">Call Us</a>
                            </li>
                                                    <li>
                                <a href="/contact-us/email-us">Email Us</a>
                            </li>
                                                    <li>
                                <a href="/contact-us/visit-us">Visit Us</a>
                            </li>
                                                    <li>
                                <a href="/contact-us/submit-medical-inquiry">Submit a Medical Inquiry</a>
                            </li>
                                                    <li>
                                <a href="/contact-us/submit-media-inquiry">Submit a Media Inquiry</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/medical-professionals">For Medical Professionals</a>
                    </li>
                                                                        <li>
                                <a href="/medical-professionals/medicines">Our Medicines &amp; Products</a>
                            </li>
                                                    <li>
                                <a href="/medical-professionals/pipeline">Our Pipeline</a>
                            </li>
                                                    <li>
                                <a href="/medical-professionals/medinfo">Medical Resources</a>
                            </li>
                                                    <li>
                                <a href="/medical-professionals/clinical-trial-information">Clinical Trial Information</a>
                            </li>
                                                    <li>
                                <a href="/medical-professionals/sunshine-act-compliance">Sunshine Act Compliance</a>
                            </li>
                                                    <li>
                                <a href="/medical-professionals/product-security">Product Security</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/partners">For Partners</a>
                    </li>
                                                                        <li>
                                <a href="/partners/our-approach">Our Approach</a>
                            </li>
                                                    <li>
                                <a href="/partners/what-we-are-looking-for">What We Are Looking For</a>
                            </li>
                                                    <li>
                                <a href="/partners/partner-with-us">Partner With Us</a>
                            </li>
                                                    <li>
                                <a href="/partners/contacts">Contact Us</a>
                            </li>
                                                    <li>
                                <a href="/partners/our-stories">Our Stories</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/scientists">For Scientists</a>
                    </li>
                                                                        <li>
                                <a href="/scientists/our-scientists">Our Scientists</a>
                            </li>
                                                    <li>
                                <a href="/scientists/our-pipeline">Our Pipeline</a>
                            </li>
                                                    <li>
                                <a href="/scientists/behind-the-science">Our Stories</a>
                            </li>
                                                    <li>
                                <a href="/scientists/our-podcast">Our Podcast</a>
                            </li>
                                                    <li>
                                <a href="/scientists/publications">Publications</a>
                            </li>
                                                    <li>
                                <a href="/scientists/mta">MTA Program</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/media">For Media</a>
                    </li>
                                                                        <li>
                                <a href="/media/news-features">News Features</a>
                            </li>
                                                    <li>
                                <a href="/media/press-releases">Press Releases</a>
                            </li>
                                                    <li>
                                <a href="/media/statements">Statements</a>
                            </li>
                                                    <li>
                                <a href="/media/company-information">Company Information</a>
                            </li>
                                                    <li>
                                <a href="/media/news-alerts">Sign Up For News Alerts</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/good">For Good</a>
                    </li>
                                                                        <li>
                                <a href="/good/giving">Giving</a>
                            </li>
                                                    <li>
                                <a href="/good/sustainability">Sustainability</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/inclusion-belonging"> Inclusion &amp; Belonging</a>
                    </li>
                                                                        <li>
                                <a href="/inclusion-belonging/transforming-society">Transforming Society</a>
                            </li>
                                                            </ul>
                            <ul>
                    <li class="first-level">
                        <a href="/careers">Now Hiring</a>
                    </li>
                                                                        <li>
                                <a href="/careers/find-a-job">Find A Job</a>
                            </li>
                                                    <li>
                                <a href="/careers/professional-areas">Professional Areas</a>
                            </li>
                                                            </ul>
                        <ul>
                <li class="first-level">
                        <a>&mdash;</a>
                </li>
                <li><button id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</button></li>
                <li><a href="/privacy-policy">Privacy Policy</a></li>
                <li><a href="/wa-consumer-health-data-privacy-policy">WA Consumer Health Data Privacy Policy</a></li>
                <li><a href="/terms-conditions">Terms &amp; Conditions</a></li>
                <li><a href="/accessibility">Accessibility</a></li>
            </ul>
        </nav>
    </div>
    <div class="constrained">
        <div class="footer-social">
            <div class="footer-social-list">
                <a href="//facebook.com/genentech" target="_blank" data-service="facebook">
                    <svg>
                        <use xmlns:xlink="http://www.w3.org/1999/xlink"
                                xlink:href="#icon-facebook"></use>
                    </svg>
                </a>
                <a href="//twitter.com/genentech" target="_blank" data-service="twitter">
                    <svg>
                        <use xmlns:xlink="http://www.w3.org/1999/xlink"
                                xlink:href="#icon-twitter"></use>
                    </svg>
                </a>
                <a href="//linkedin.com/company/genentech" target="_blank"
                    data-service="linkedin">
                    <svg>
                        <use xmlns:xlink="http://www.w3.org/1999/xlink"
                                xlink:href="#icon-linkedin"></use>
                    </svg>
                </a>
                <a href="//youtube.com/genentech" target="_blank" data-service="youtube" style="padding: 5% 0%;">
                    <svg>
                        <use xmlns:xlink="http://www.w3.org/1999/xlink"
                                xlink:href="#icon-youtube"></use>
                    </svg>
                </a>
                <a href="//pinterest.com/genentech" target="_blank" data-service="pinterest">
                    <svg>
                        <use xmlns:xlink="http://www.w3.org/1999/xlink"
                                xlink:href="#icon-pinterest"></use>
                    </svg>
                </a>
                <a target="_blank" href="https://www.glassdoor.com/Overview/Working-at-Genentech-EI_IE274.11,20.htm" style="display: flex; align-items: center;">
                    <svg style="height: 22px;">
                        <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-glassdoor" data-service="glassdoor"></use>
                    </svg>
                </a>
                <a href="//instagram.com/genentech" target="_blank" data-service="instagram">
                    <svg>
                        <use xmlns:xlink="http://www.w3.org/1999/xlink"
                                xlink:href="#icon-instagram"></use>
                    </svg>
                </a>
            </div>
        </div>
    </div>
    <div class="constrained">
        <div class="copyright">&copy; 2025 Genentech, Inc. All rights reserved. This site is intended for US residents only.</div>
    </div>
</div>


<link rel="modulepreload" href="https://www.gene.com/build/assets/header-DHsyHU1q.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/index-C7jJ30-R.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/_commonjsHelpers-D6-XlEtG.js" /><script type="module" src="https://www.gene.com/build/assets/header-DHsyHU1q.js"></script>
<script type="text/javascript" src="https://www.gene.com/assets/frontend/js/custom/galaxySearch.js"></script>

<script src="/assets/frontend/js/vendor/jquery-1.7.2.min.js"></script>
<script src="/assets/frontend/js/vendor/select2/dist/js/select2.full.min.js"></script>
<script src="/assets/frontend/js/vendor/magnific-popup/dist/jquery.magnific-popup.min.js"></script>
<script src="/assets/frontend/js/vendor/FitText.js/jquery.fittext.js"></script>

<link rel="preload" as="style" href="https://www.gene.com/build/assets/main-site-Dfl99_9r.css" /><link rel="modulepreload" href="https://www.gene.com/build/assets/gene-scripts-f_I1C7nR.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/main-site-BXI8k-3U.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/_commonjsHelpers-D6-XlEtG.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/base-component-BNXLcCNA.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/window-events-UQDrRXbt.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/product-select-Bchy5aCf.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/icons-loader-BY2iGxc9.js" /><link rel="stylesheet" href="https://www.gene.com/build/assets/main-site-Dfl99_9r.css" /><script type="module" src="https://www.gene.com/build/assets/gene-scripts-f_I1C7nR.js"></script><script type="module" src="https://www.gene.com/build/assets/main-site-BXI8k-3U.js"></script><script type="module" src="https://www.gene.com/build/assets/product-select-Bchy5aCf.js"></script><script type="module" src="https://www.gene.com/build/assets/icons-loader-BY2iGxc9.js"></script>

    
    <script src="/assets/frontend/js/custom/datatables.js"></script>

<script>
    jQ.unq();
    jQuery(function() {
        // Initialize custom classes
        for (var classname in Gene.custom) {
            if (classname != 'configs') {
                Gene.custom[classname].init();
            }
        }
    });
</script>



</body>
</html>
